Literature DB >> 3339327

The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice.

E G Routledge1, M M Willcocks, A C Samson, L Morgan, R Scott, J J Anderson, G L Toms.   

Abstract

The fusion (F) glycoprotein, large glyco- (G) protein, phospho- (P) protein and 22K protein of respiratory syncytial (RS) virus A2 strain were purified by a combination of immunoaffinity adsorption and preparative SDS-PAGE. All four proteins elicited serum antibody in mice after repeated inoculation in adjuvant, although the magnitude of the response as measured by ELISA varied from mouse to mouse. The F protein generated neutralizing antibodies in only 50% of the mice determined to be seropositive by ELISA. The G protein also induced neutralizing antibodies but in this instance neutralization tests and ELISA titres were more closely correlated. No neutralizing activity was detected in mice immunized with the P or 22K proteins although all produced antibody detectable by ELISA. Mice immunized with either the F or the G protein were found to be protected against subsequent RS virus challenge, whether they had developed neutralizing antibody or not. Mice inoculated with the P or 22K proteins were not protected.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339327     DOI: 10.1099/0022-1317-69-2-293

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

2.  Analysis of murine coronavirus surface glycoprotein functions by using monoclonal antibodies.

Authors:  E Routledge; R Stauber; M Pfleiderer; S G Siddell
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  Comparison of caprine, human and bovine strains of respiratory syncytial virus.

Authors:  M Trudel; F Nadon; C Simard; F Bélanger; R Alain; C Séguin; G Lussier
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 4.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

Authors:  Shannon I Phan; Zhenhai Chen; Pei Xu; Zhuo Li; Xiudan Gao; Stephanie L Foster; Michael N Teng; Ralph A Tripp; Kaori Sakamoto; Biao He
Journal:  Vaccine       Date:  2014-04-08       Impact factor: 3.641

Review 6.  Respiratory syncytial virus: virology, diagnosis, and vaccination.

Authors:  G L Toms
Journal:  Lung       Date:  1990       Impact factor: 2.584

7.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Epitope specificities of human serum antibodies reactive with respiratory syncytial virus fusion protein.

Authors:  B S Robinson; J S Everson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Interferon alfa, infectious virus, and virus antigen secretion in respiratory syncytial virus infections of graded severity.

Authors:  C E Taylor; M S Webb; A D Milner; P D Milner; L A Morgan; R Scott; G M Stokes; A S Swarbrick; G L Toms
Journal:  Arch Dis Child       Date:  1989-12       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.